Order Name (ชื่อการทดสอบ):
Pharmacogenomics of cardiovascular drugs (CYP2C19, CYP2C9, VKORC1, SLCO1B1 - Fast track)
Clinical Information (ข้อมูลทางคลินิก):
CYP2C19 is an important drug metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants, clopidogrel, voriconazole, and proton pump inhibitors. This test identifies 11 Single Nucleotide Polymorphisms (SNPs) (*1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *17, *35) by Real-time PCR. This CYP2C19 detection test covers two known no functional alleles and one known rapid functional allele.
CYP2C9 is an important drug metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including phenytoin, angiotensin II blockers, non-steroidal anti-inflammatory drugs, the alkylating anticancer prodrugs. This test identifies three common alleles (*1, *2, *3) by Real-time PCR. The CYP2C9 genotyping (2 SNP; Fast track) test covers two known no functional alleles.
CYP2C9 and VKORC1 are an important drug metabolizing enzyme that catalyzes the biotransformation of warfarin. Inherited differences in VKORC1 increase or decrease the amount of warfarin needed to inhibit the formation of the clotting factors. When the amount of warfarin exceeds what is needed, the risk of bleeding is increased. This test identifies three common alleles in CYP2C9 (*1, *2, *3) and one common allele in VKORC1 by Real-time PCR.
SLCO1B1 is an influx transporter that moves drugs into cells. Variations in SLCO1B1 may affect the blood levels of drugs that are substrates for this transporter. Statins are one of the most common classes of medications affected by this transporter. Variations that result in decreased transporter activity may result in increased statin blood levels and increase the risk of adverse effects, such as myalgia and rhabdomyolysis. SLCO1B1-based dosing guidelines are available for statins. Providers should consider genotyping patients who are initiating statin therapy or those who have experienced adverse effects to statins in the past. Genetic variants tested for SLCO1B1 are *1,*5, *15,*37.